drugset
Drugs / PEP-3
last change Nov 2016 re-read 3 minutes ago

PEP-3

also known as PEP-3 vaccine · PEP-3-KLH

Vaccine targets EGFR via depletion

Developed for
brain cancer
Investigated by
John Sampson · National Institute of Neurological Disorders and Stroke (NINDS)

Trials 1

today NCT00643097 · Ph 2
20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00643097 Sep 2007 → Jan 2012 brain cancer John Sampson Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as PEP-3 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00643097 ↗
Known as PEP-3 vaccine “Patients first receive 3 initial vaccinations of an epidermal growth factor receptor variant III (EGRRvIII)-specific peptide (PEP-3) keyhole limpet hemocyanin (KLH) conjugate...” NCT00643097 ↗
Known as PEP-3-KLH “PEP-3-KLH conjugate vaccine” NCT00643097 ↗
Action Deplete “EGFRvIII-targeted vaccination induces patient immune responses despite therapeutic TMZ-induced lymphopenia and eliminates EGFRvIII-expressing tumor cells without autoimmunity.” PMID 21149254 ↗ Dec 2010
Modality Vaccine “EGFRvIII-targeted peptide vaccine” PMID 20921459 ↗ Oct 2010
Target EGFR “EGFRvIII-targeted peptide vaccine” PMID 20921459 ↗ Oct 2010